Ranbaxy launched generic Lipitor on November 30, 2011. Pfizer’s exclusivity ended that day. If a payer or brand team modeled
Stop Budgeting for Generic Entry as a Single Date: Multi-Source Entry Happens in Waves Read Post »
USPTO maintenance fees on a single utility patent jump from $2,150 to $4,040 to $8,280 across three fixed windows for
The Three-Year Explosion: Why “File Early, File Often” Bankrupts Small IP Budgets Read Post »
In February, March, and April 2017, twenty-five generic drug companies sent Bristol-Myers Squibb and Pfizer formal notice that they had
On September 12, 2025, a Delaware jury awarded Mallinckrodt Pharmaceuticals roughly $9.5 million against Airgas Healthcare for infringing patents covering
The At-Risk Launch Damages Model Still Runs on 2015 Math Read Post »
In January 2022, Lonza Walkersville and its joint-venture partner Octane Biotech sued Miltenyi Biotec in the District of Maryland, alleging
On April 22, 2014, the Federal Circuit vacated a patent infringement judgment that Gilead Sciences had already won. The drug
The Double Patenting Defense That Nearly Erased Tamiflu’s Last Patent Read Post »
Nine separate patent holders have asserted rights against a single COVID-19 vaccine, Comirnaty, since August 2022. Two more have asserted
mRNA Platform Patents Are Colliding. Here Is What That Means For The Next Filer Read Post »
On August 18, 2023, the FDA approved Eylea HD, Regeneron’s 8 mg reformulation of its blockbuster eye drug aflibercept. Nine
In October 2001, the United States government came within a phone call of doing something it had never done to
The Compulsory License Nobody Expects Until a Government Invokes It Read Post »
Sign in or create a free account to read this DrugPatentWatch article
